Global smartwatch market was valued at $40.7 billion in 2025 and is growing at a CAGR of 8.0% during the forecast period (2026-2035). Smartwatches play a significant role in medical and health monitoring by providing continuous, real-time tracking of key physiological parameters. They measure heart rate, blood oxygen levels, sleep patterns, and stress indicators, enabling users to gain insights into their overall well-being. Advanced models offer electrocardiogram (ECG) and irregular heartbeat detection, assisting in early identification of potential health issues. Integration with mobile health apps allows data storage, trend analysis, and sharing with healthcare providers. By combining convenience with proactive monitoring, smartwatches support preventive care, encourage healthier lifestyles, and empower individuals to make informed decisions about their health.

Sleep aid market was valued at $48.5 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Growing recognition of sleep disorders, coupled with rising stress levels worldwide, is fueling the demand for more effective insomnia treatments, thereby driving the expansion of the sleep aid market. In line with this trend, pharmaceutical companies are increasingly focusing on developing novel therapies that target the underlying mechanisms of sleep regulation. For instance, in August 2025, Eisai launched its in-house developed anti-insomnia drug DAYVIGO (lemborexant) in China for treating adults with insomnia, impacting sleep onset and maintenance. DAYVIGO is a dual orexin receptor antagonist, acting by competitively binding to OX1R and OX2R receptors, regulating sleep-wake rhythm differently than conventional treatments like benzodiazepines. 

Global protein engineering market was valued at $3.5 billion in 2025 and is growing at a CAGR of 16.4% during the forecast period (2026-2035). Increasing investments in R&D for monoclonal antibodies, engineered proteins, and next-generation biologics are driving market growth and fueling demand for efficient protein engineering solutions. Additionally, this trend is reflected in recent funding activities that support the development of integrated, in-house protein engineering and validation capabilities aimed at accelerating antibody and biologics discovery. For instance, in January 2026, Nuclera successfully extended its Series C funding to a total of $87 million, including an additional $12 million financing extension aimed at enhancing its eProtein Discovery capabilities for antibody engineering. The funding, led by Elevage Medical Technologies and Jonathan Milner, 

Global Probiotics market was valued at $76.2 billion in 2025 and is growing at a CAGR of 8.2% during the forecast period (2026-2035). Probiotics are live microorganisms that, when consumed in adequate amounts, support the balance of beneficial bacteria in the human body, particularly in the digestive system. They are commonly incorporated into foods, beverages, and dietary supplements due to their association with digestive health and overall well-being. Probiotics function by helping maintain microbial balance, supporting normal gut function, and contributing to the body’s natural defense mechanisms. Their use has expanded beyond traditional dairy products into a wider range of food and beverage formats, reflecting changing consumer preferences and advancements in formulation and storage technologies. Probiotic-enriched dairy products dominate the market due to high consumer demand for gut health, digestive benefits, and overall wellness. For instance,

Global power bank market was valued at $14.0 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Growing deployment of utility-scale renewable technologies, including solar, battery energy storage, and hybrid projects, is revealing a heightened necessity for interconnection deposits, which in turn necessitates structured financing solutions to effectively progress projects through development pipelines, thereby driving market growth. This trend is increasingly reflected in recent financing arrangements within the renewable energy development ecosystem, where dedicated capital is being used to address upfront interconnection requirements and accelerate project advancement. For instance, in December 2025, $8 million loan secured by PowerBank will fund interconnection deposits for a portfolio of 34 MW of solar power, battery energy storage, and hybrid projects.

Global non-invasive cancer diagnosis market was valued at $38.6 billion in 2025 and is growing at a CAGR of 12.2% during the forecast period (2026-2035). Molecular diagnostics play a critical role in the global non-invasive cancer diagnosis market by enabling highly sensitive detection of circulating tumor DNA (ctDNA) and other biomarkers in blood. These tests support early identification of cancer recurrence and residual disease, often months before conventional imaging methods can detect abnormalities. By providing precise, real-time insights, molecular diagnostics allow clinicians to personalize monitoring strategies, optimize treatment decisions, and improve patient outcomes. The minimally invasive nature of these tests enhances patient compliance and reduces reliance on traditional biopsies, driving adoption across healthcare systems and contributing significantly to the growth and innovation of the non-invasive cancer diagnosis market.

The global lung cancer therapeutics market was valued at $37,500 million in 2024 and is growing at a CAGR of 10.3% during the forecast period (2026-2035). Regulatory validation of next-generation immunotherapies is increasing physician confidence and shifting the market from traditional chemotherapy to immune-based treatments, thereby accelerating the adoption of advanced immunotherapy for advanced small-cell lung cancer. This trend is evidenced by recent regulatory actions supporting novel immunotherapies. For instance, in November 2025, FDA granted full approval to the immunotherapy drug tarlatamab (Imdelltra) for adults with advanced small-cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. Tarlatamab functions as a bispecific T cell engager, linking tumor cells to T cells to enhance the immune response against cancer. In a study of 509 patients, those treated with tarlatamab exhibited a 40% reduction in death risk compared to standard chemotherapy, even among patients with extensive disease spread, where the five-year survival rate is typically below 10%.

Global LED services market was valued at $24.3 billion in 2025 and is growing at a CAGR of 6.0% during the forecast period (2026-2035). The automotive industry plays a significant role in the LED services market by driving demand for advanced lighting solutions that enhance vehicle safety, efficiency, and aesthetics. LEDs are increasingly used in headlights, taillights, interior lighting, and dashboard displays due to their energy efficiency, long lifespan, and design flexibility. Automakers are adopting high-brightness and adaptive LED technologies to meet regulatory standards and consumer expectations for improved visibility and styling. This trend also encourages innovation in sustainable lighting and smart systems, positioning the automotive sector as a key contributor to the growth and evolution of the global LED services market.

Global flight management system market was valued at $5.8 billion in 2025 and is growing at a CAGR of 6.4% during the forecast period (2026-2035). Narrow-body aircraft play an essential role in the flight management system (FMS) market, as airlines increasingly deploy them for both short-haul and longer international routes due to improved fuel efficiency and extended range. FMS integration in these aircraft ensures precise navigation, optimized fuel consumption, and efficient route planning, enhancing operational performance. Key components such as flight management computers (FMC), control display units (CDU), and visual display units (VDU) work seamlessly to support autopilot, performance monitoring, and real-time decision-making. The rising adoption of modern narrow-body fleets drives demand for advanced FMS solutions, supporting airline cost efficiency and network flexibility.

Global coronary stent market was valued at $10.9 billion in 2025 and is growing at a CAGR of 5.1% during the forecast period (2026-2035). Balloon-expandable stents play a central role in coronary stent interventions due to their controlled deployment, precise positioning, and strong radial support, which are critical in treating coronary artery disease. These stents are expanded using an inflatable balloon, allowing clinicians to achieve accurate placement within narrowed coronary arteries. The predictable expansion behavior supports optimal vessel scaffolding and uniform lesion coverage during percutaneous coronary interventions. Balloon-expandable stents are widely compatible with advanced drug-eluting technologies, contributing to reduced restenosis rates and improved long-term outcomes. The extensive clinical use, established procedural familiarity, and consistent performance across a wide range of coronary lesions reinforce their continued importance in coronary revascularization practices globally.